- Home
- FHTX vs CLBR Comparison
FHTX vs CLBR Comparison
Compare FHTX & CLBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- CLBR
- Stock Information
- Founded
- FHTX 2015
- CLBR 2023
- Country
- FHTX United States
- CLBR United States
- Employees
- FHTX N/A
- CLBR N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- CLBR
- Sector
- FHTX Health Care
- CLBR
- Exchange
- FHTX Nasdaq
- CLBR Nasdaq
- Market Cap
- FHTX 237.4M
- CLBR 230.6M
- IPO Year
- FHTX 2020
- CLBR 2023
- Fundamental
- Price
- FHTX $5.23
- CLBR $10.75
- Analyst Decision
- FHTX Strong Buy
- CLBR
- Analyst Count
- FHTX 6
- CLBR 0
- Target Price
- FHTX $13.17
- CLBR N/A
- AVG Volume (30 Days)
- FHTX 163.3K
- CLBR 174.2K
- Earning Date
- FHTX 03-06-2025
- CLBR 01-01-0001
- Dividend Yield
- FHTX N/A
- CLBR N/A
- EPS Growth
- FHTX N/A
- CLBR N/A
- EPS
- FHTX N/A
- CLBR N/A
- Revenue
- FHTX $25,515,000.00
- CLBR N/A
- Revenue This Year
- FHTX N/A
- CLBR N/A
- Revenue Next Year
- FHTX $8.30
- CLBR N/A
- P/E Ratio
- FHTX N/A
- CLBR $137.78
- Revenue Growth
- FHTX N/A
- CLBR N/A
- 52 Week Low
- FHTX $3.86
- CLBR $10.15
- 52 Week High
- FHTX $10.25
- CLBR $12.28
- Technical
- Relative Strength Index (RSI)
- FHTX 52.39
- CLBR 37.79
- Support Level
- FHTX $3.89
- CLBR $10.73
- Resistance Level
- FHTX $6.27
- CLBR $11.27
- Average True Range (ATR)
- FHTX 0.59
- CLBR 0.08
- MACD
- FHTX 0.11
- CLBR 0.00
- Stochastic Oscillator
- FHTX 48.38
- CLBR 9.43
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About CLBR Colombier Acquisition Corp. II
Colombier Acquisition Corp II is a blank check company.